Agomab Therapeutics NVAGMB
13F holders, Q2 2026 (June 30)34holders +2
9new positions
7sold out
$12.98avg. 13F price*
At the end of Q2 2026, 34 institutions reported holding Agomab Therapeutics NV (AGMB) in their 13F filings, up 2 from Q1 2026. 9 opened new positions and 7 sold out. The largest holders were EQT Fund Management S.a r.l. ($66.7M), Sanofi ($36.1M) and Redmile Group, LLC ($35.5M).
- Company
- Agomab Therapeutics NV
- CUSIP
- 00860C102
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q1 2026 → Q2 2026
| Institutions | Total Value | |
|---|---|---|
| New Positions | 9 | $3.7M |
| Exits | 7 | $6.1M |
All 13F filers, Q1 2026 → Q2 2026: 3,374,484 shares bought and 773,229 shares sold, net +2,601,255 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 34 holders
| EQT Fund Management S.a r.l. | 7.74% | No change | 5,141,992 | $66.7M |
| Sanofi | 6.76% | No change | 2,783,096 | $36.1M |
| Redmile Group, LLC | 2.38% | Add +1649.7% | 2,733,926 | $35.5M |
| Cormorant Asset Management, LP | 1.64% | No change | 2,465,348 | $32.0M |
| TCG Crossover Management, LLC | 0.64% | No change | 2,053,233 | $26.7M |
| Federated Hermes, Inc. | 0.03% | No change | 1,618,000 | $21.0M |
| Nantahala Capital Management, LLC | 1.23% | Add +30.7% | 1,568,188 | $20.4M |
| Casdin Capital, LLC | 1.01% | No change | 1,550,000 | $20.1M |
| Andera Partners | 9.67% | No change | 1,538,702 | $20.0M |
| FMR LLC | 0.00% | No change | 1,458,677 | $18.9M |
| Aberdeen Group plc | 0.02% | Add +19.6% | 846,695 | $11.0M |
| Samsara Biocapital, LLC | 0.64% | No change | 600,000 | $7.8M |
| Perceptive Advisors LLC | 0.12% | No change | 600,000 | $7.8M |
| Siren, L.L.C. | 0.11% | No change | 411,250 | $5.3M |
| Orbimed Advisors LLC | 0.05% | New | 192,740 | $2.5M |
| Pfizer Inc | 0.61% | No change | 75,000 | $1.0M |
| Alps Advisors Inc. | 0.00% | New | 49,984 | $649K |
| Bellevue Group AG | 0.01% | Reduce -1.5% | 49,248 | $639K |
| Seven Grand Managers, LLC | 0.03% | Reduce -76.2% | 47,600 | $618K |
| Sectoral Asset Management Inc. | 0.39% | No change | 43,500 | $565K |
| Burkehill Global Management, LP | 0.02% | No change | 35,000 | $454K |
| Quadrature Capital Ltd | 0.00% | New | 20,461 | $266K |
| Two Sigma Investments, LP | 0.00% | Add +26.9% | 18,072 | $235K |
| HRT Financial LP | 0.00% | Reduce -28.0% | 17,075 | $221K |
| Goldman Sachs Group Inc. | 0.00% | Reduce -67.0% | 11,800 | $153K |
| XTX Topco Ltd | 0.00% | New | 10,271 | $133K |
| Citigroup Inc. | 0.00% | New | 9,496 | $123K |
| UBS Group AG | 0.00% | Reduce -66.9% | 2,128 | $28K |
| GAMMA Investing LLC | 0.00% | New | 1,344 | $17K |
| Morgan Stanley | 0.00% | Reduce -60.3% | 1,200 | $16K |
| BNP Paribas Financial Markets | 0.00% | New | 754 | $10K |
| Larson Financial Group LLC | 0.00% | New | 698 | $9K |
| SBI Securities Co., Ltd. | 0.00% | No change | 2 | $26 |
| Caitong International Asset Management Co., Ltd | 0.00% | New | 2 | $26 |
"% of holder's portfolio" is AGMB's weight in each manager's 13F, not the share of Agomab Therapeutics NV the manager owns.